ertising (trading +8.5%) • SocGen O2 revs & EBIT beat, CIB & French retail strong, confident outlook, no rights issue (trading +8.7%) • Sanofi O2 EPS & pharma sales miss on generic comp, patent concerns, lowers FY forecasts (trading -6.2%) • Arcelor O2 sales inline, EBITDA small ahead, cost improvement pl